Elucidation of the mechanism of osteocalcin against both vascular calcification and development of cardiovascular disease in type 2 diabetes

Elucidation of the mechanism of osteocalcin against both vascular calcification and development of cardiovascular disease in type 2 diabetes - Elucidation of the mechanism of osteocalcin against both vascular calcification and development of cardiovascular disease in type 2 diabetes

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041560

Enrollment

500

Registered

2020-08-26

Start date

2018-10-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Type 2 Diabetes patients 2. Patients not according to exclusion criteria

Exclusion criteria

Exclusion criteria: 1. Patients treated with hormone drugs and immunosuppressant 2. Patients with malignant disease 3. Pregnancy patients 4. Patients with diabetic ketoacidosis, diabetic coma, or pre-coma 5. Patients with severe infection, or in case of emergency

Design outcomes

Primary

Measure	Time frame
The association between serum osteocalcin and undercarboxylated osteocalcin levels and the progression of thoracic artery calcification.	—

Secondary

Measure	Time frame
The association between serum osteocalcin and undercarboxylated osteocalcin levels and the progression of atherosclerosis.	—

Countries

Japan

Contacts

Public ContactWatanabe Kentaro

Nihon University School of Medicine Division of Diabetes and Metabolic Diseases, Department of Internal Medicine

watanabe.kentaro@nihon-u.ac.jp0339728111

Outcome results